Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.48 |
| ▸ | JAK1 | P23458 | 3/20 | 0.48 |
| ▸ | TYK2 | P29597 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | BCL9 | O00512 | 4/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171529 | 0.82 | JAK2 (0.50) | JAK2JAK1TYK2JAK3SMN1; SMN2 | |
| SCHEMBL13490506 | 0.81 | JAK2 (0.55) | JAK2JAK1TYK2JAK3SMN1; SMN2 | |
| SCHEMBL12953316 | 0.78 | JAK2 (0.47) | JAK2JAK1TYK2JAK3SMN1; SMN2 | |
| SCHEMBL171371 | 0.78 | JAK2 (0.48) | JAK2JAK1TYK2JAK3SMN1; SMN2 | |
| SCHEMBL29087342 | 0.78 | SMN1; SMN2 (0.59) | JAK2JAK1TYK2JAK3SMN1; SMN2 | |
| SCHEMBL1437263 | 0.77 | SMN1; SMN2 (0.59) | JAK2JAK1TYK2JAK3SMN1; SMN2 | |
| SCHEMBL171366 | 0.77 | JAK2 (0.47) | JAK2JAK1TYK2JAK3SMN1; SMN2 | |
| SCHEMBL9962360 | 0.76 | ENPP2 (0.49) | JAK2JAK1TYK2JAK3SMN1; SMN2 | |
| SCHEMBL14314308 | 0.76 | SMN1; SMN2 (0.47) | JAK2JAK1TYK2JAK3SMN1; SMN2 | |
| SCHEMBL2876671 | 0.76 | ENPP2 (0.49) | JAK2JAK1TYK2JAK3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530662-B2 | Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20100029947-A1 | Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them | FUJIFILM FINECHEMICALS CO., LTD | 2010-02-04 | — | — | US | disclosed |
| US-7632950-B2 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2009-12-15 | — | — | US | disclosed |
| US-20070093528-A1 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | FUJIFILM FINECHEMICALS CO., LTD (JP) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029947-A1 | Pyridyltetrahydropyridines and Pyridylpiperidines, and Method of Manufacturing Them | QDPR, HRH4, HRH2 | JAK2 2028/4885JAK1 4058/4885TYK2 991/4885 |
| US-20070093528-A1 | Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them | QDPR, HRH4, HRH2 | JAK2 2058/4885JAK1 4106/4885TYK2 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.